

OFFICE OF FISCAL ANALYSIS

Legislative Office Building, Room 5200
Hartford, CT 06106 ◊ (860) 240-0200
<http://www.cga.ct.gov/ofa>

sSB-307

AN ACT CONCERNING MEDICAID COVERAGE OF BIOMARKER TESTING.

As Amended by Senate "A" (LCO 3931)

Senate Calendar No.: 211

OFA Fiscal Note

State Impact: None

Municipal Impact: None

Explanation

The bill, which requires Medicaid coverage of biomarker testing for the purpose of diagnosis, treatment, appropriate management or ongoing monitoring of a Medicaid enrollee's disease or condition, is not anticipated to result in a fiscal impact as such testing is currently covered.

Senate "A" strikes the language in the underlying bill and the associated fiscal impact and results in the fiscal impact described above.

The Out Years

The annualized ongoing fiscal impact identified above would continue into the future subject to the conditions on which biomarker testing is covered.

The preceding Fiscal Impact statement is prepared for the benefit of the members of the General Assembly, solely for the purposes of information, summarization and explanation and does not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

Primary Analyst: LD
Contributing Analyst(s): ES
Reviewer: RW

4/18/24